Elanco Animal Health (NYSE:ELAN) Issues Quarterly Earnings Results

Elanco Animal Health (NYSE:ELAN) released its quarterly earnings results on Wednesday. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.08, Briefing.com reports. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The firm’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period last year, the company earned $0.45 EPS.

Elanco Animal Health Price Performance

ELAN stock traded up $0.31 during trading on Thursday, hitting $17.21. The company had a trading volume of 7,407,675 shares, compared to its average volume of 4,585,274. The company has a current ratio of 2.75, a quick ratio of 1.35 and a debt-to-equity ratio of 0.92. The business has a 50 day moving average of $14.98 and a 200 day moving average of $14.04. Elanco Animal Health has a fifty-two week low of $7.88 and a fifty-two week high of $17.43. The firm has a market capitalization of $8.50 billion, a price-to-earnings ratio of -6.79, a P/E/G ratio of 1.42 and a beta of 1.34.

Insiders Place Their Bets

In related news, Director R David Hoover acquired 20,000 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the acquisition, the director now owns 185,000 shares in the company, valued at $2,985,900. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.57% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ELAN has been the topic of a number of analyst reports. Barclays lifted their price objective on shares of Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday. TheStreet upgraded shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research note on Friday, February 23rd. Morgan Stanley lifted their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Finally, The Goldman Sachs Group lifted their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus target price of $17.29.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.